ArticleEuropean journal of medical research2026
Lactylation-driven gene signatures define breast cancer prognosis: a predictive model and insights into immune microenvironment dynamics.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A lactylation-related gene signature predicts prognosis and immunotherapy response in clear cell renal cell carcinoma based on machine learning and multi-omics analysis.Discover oncology · 2026Article
- Lactylation-mediated remodelling of the breast cancer microenvironment: single-cell multidimensional analysis and prognostic model construction.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a leading cause of cancer-related mortality worldwide, with poor prognosis largely due to its invasive and metastatic nature. Tumor lactylation plays a crucial role in cancer progression by influencing immune modulation and metabolic reprogramming. This study aimed to identify lactylation-related gene signatures associated with breast cancer prognosis and develop a predictive survival model.
methodsBioinformatics analyses were performed using RNA-seq and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. An unsupervised consensus clustering analysis was applied to classify breast cancer samples into distinct groups based on lactylation-related gene expression. Differentially expressed genes (DEGs) between clusters were identified and subjected to functional enrichment analysis. To assess immune-related differences between groups, the ESTIMATE and CIBERSORT algorithms were used, along with an analysis of human leukocyte antigen (HLA) and immune checkpoint molecule expression levels, to explore the relationship between lactylation and the breast cancer immune microenvironment. A prognostic model was constructed using univariate Cox and Lasso regression analyses, followed by validation. Machine learning techniques identified key biomarkers, which were further analyzed for clinical relevance. Additionally, single-cell clustering was performed to investigate the expression patterns of these genes within the breast cancer microenvironment.
resultsConsensus clustering identified two distinct groups: high and low lactylation. Differentially expressed genes were enriched in pathways related to cytokine-cytokine receptor interaction, immune response, cell activation, and adhesion. Lactylation-related genes were found to influence immune cell infiltration in the breast cancer microenvironment. Thirty-seven prognostic lactylation-related genes were identified through univariate Cox regression and used to develop a predictive model. The high-risk group was associated with poorer survival, and the model's performance was validated in the GEO cohort. Specific hub genes involved in immune modulation and malignant cell proliferation were also identified.
conclusionWe successfully developed a lactylation-based prognostic model that can assess breast cancer prognosis and potentially guide personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.